Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer-Reference-Cited by-同舟云学术

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer

Published:2016-01-22 Issue:12 Volume:22 Page:2855-2864
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Rodler Eve T.,Kurland Brenda F.,Griffin Melissa,Gralow Julie R.,Porter Peggy,Yeh Rosa F.,Gadi Vijayakrishna K.,Guenthoer Jamie,Beumer Jan H.,Korde Larissa,Strychor Sandra,Kiesel Brian F.,Linden Hannah M.,Thompson John A.,Swisher Elizabeth,Chai Xiaoyu,Shepherd Stacie,Giranda Vincent,Specht Jennifer M.

Funder

National Cancer Institute

Fred Hutchinson Cancer Research Center; AbbVie Laboratories; Safeway Gift Fund; and Mullen Gift Fund

University of Pittsburgh Cancer Institute (UPCI) Biostatistics Shared Resource Facility and the (UPCI) Cancer PK and Pharmacodynamics Facility

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small molecule agents for triple negative breast cancer: Current status and future prospects;Translational Oncology;2024-03

2. Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study;Surgery Open Science;2023-12

3. The Current Role of Neoadjuvant Chemotherapy in the Management of HER2-Positive, Triple-Negative, and Micropapillary Breast Cancer: A Narrative Review;Cureus;2023-11-30

4. Unlocking Therapeutic Potential of Poly(Adenosine Diphosphate Ribose) Polymerase (PARP) Inhibitors in Metastatic Breast Cancer With BRCA Gene Mutations: A Narrative Review;Cureus;2023-10-03

5. Identification and evaluation of a novel PARP1 inhibitor for the treatment of triple-negative breast cancer;Chemico-Biological Interactions;2023-09